BackgroundCalcineurin inhibitors are associated with adverse cardiac effects. Mammalian target of rapamycin inhibitors have been reported to have beneficial effects on cardiac function. We used advanced echocardiographic techniques in a randomized controlled trial to examine cardiac responses to an everolimus-based arm versus a calcineurin inhibitor–based arm in de novo kidney transplant recipients. MethodsThis was a substudy of the Certican Nordic Trial in Renal Transplantation study, a randomized controlled trial on safety and efficacy of early (week 7 after renal transplantation) conversion from cyclosporine A (CsA) to everolimus versus continued CsA during 1-year follow-up. A total of 44 patients (66% men; median [range] age, 61 [28–78] years) were included. All participants had a complete echocardiographic evaluation at baseline and at 1-year follow-up. ResultsLeft ventricular (LV) systolic function, LV mass, left atrial volumes, and blood pressure response did not differ between groups during 1-year follow-up. There was, however, a difference between the groups in change in peak early mitral velocity after 1 year (P=0.02), and E/e′ ratio trended higher in the everolimus group (P=0.09). ConclusionsEarly conversion from CsA-based to everolimus-based immunosuppressive treatment in de novo renal transplant recipients caused marginal changes in LV diastolic function but no effect on LV systolic function or LV mass.http://journals.lww.com/transplantjournal/Fulltext/2014/01270/Cardiac_Response_to_Early_Conversion_from.12.aspx
Sent with Reeder
Enviado desde mi iPad
No comments:
Post a Comment